Registration Complete Home » Registration Complete Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry. We will inform you of new clinical trials as information becomes available. In the meantime, feel free to access these other PF-related resources: Ofev News:Ofev May Help Treat IPF With Lung Cancer, Case Report SuggestsEsbriet, Ofev Found to Benefit IPF Patients in Clinical PracticeKL-6 Protein Found to Be a Promising Biomarker for IPF PrognosisOfev’s Ability to Slow Decline in Progressing ILDs Not Dependent on Prior TherapyGALACTIC-1 Trial of Inhaled IPF Therapy to Stop High Dose, Restrict Low DoseOfev Costs to Treat PF-ILD Should Be Reimbursed in Canada, Groups SayOfev May Be Less Tolerable Over Long Term in IPF Patients in Poorer Health IPF News:Dosing Begins in 2nd Phase 3 Trial of Antibody Treatment for IPFPhase 2 Trial of C21, Potential Oral Therapy for IPF, OpensProcalcitonin Blood Levels May Help Detect Lung Cancer in IPF Patients, Study SuggestsBiognosys, Boehringer Ingelheim Partner for Protein Studies of IPFWorld’s First Single-cell Sequencing Atlas Available for Drug Discovery in IPFIPF Hospitalizations, Mortality Rate Seen to Drop in US from 2006-16Algernon’s NP-120 Surpasses Merck’s MK-7264 in Reducing Cough Frequency in Animal Model of Acute Cough, Study Shows Esbriet News:Esbriet, Ofev Found to Benefit IPF Patients in Clinical PracticeGALACTIC-1 Trial of Inhaled IPF Therapy to Stop High Dose, Restrict Low DoseFDA Grants Priority Review to Esbriet for Unclassifiable Interstitial Lung DiseaseEsbriet Plus Anti-PD-L1 Slows Lung Cancer and Fibrosis in Mouse StudyFatigue Weighs on IPF Patients and Tends to Worsen Over Time, Study FindsGLPG1205 Safely Eases Lung Function Decline in IPF Patients, Phase 2 Trial ShowsPotential IPF Treatment, LYT-100, Shows Good Tolerability in Trial CPF News:Evel Knievel: Dedicated to Defying Death, Lost To IPFPFF Brings Daughters of PF Program Under Its WingsCPF Names 2014 Most Important Year for Pulmonary FibrosisFDA Includes CPF Advocates in IPF WorkshopCPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness MonthPFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery ChannelCoalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month IPF Clinical Trial News:UK Trial Recruiting IPF Patients to Test Nalbuphine Extended Release Tablets for Chronic CoughART-123 Doesn’t Prolong Life in IPF Acute Exacerbations, Study Says4 Factors that Impact Pulmonary Fibrosis PreventionGalecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study FindsBellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study FindsKadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PFFirst Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease FDA News:FDA Designates Axatilimab an Orphan Drug for IPFFDA Clears Potential IPF Therapy, IM156, for Phase 1 TrialFDA Grants Priority Review to Esbriet for Unclassifiable Interstitial Lung DiseaseTreprostinil Earns FDA Orphan Drug Designation for Treating IPFOfev Approved in US and Canada for Progressive Fibrosing ILDsFDA Names AMP945, Potential IPF Treatment, an Orphan DrugPediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds Author Details BNS Staff × BNS Staff